Krystal Biotech, Inc. (KRYS) has disclosed a new risk, in the Sales & Marketing category.
Krystal Biotech, Inc.’s financial vitality hinges precariously on the performance of its flagship product, VYJUVEK, having poured significant resources into its development. Despite obtaining FDA approval for treating Dystrophic Epidermolysis Bullosa (DEB), there’s no guarantee of similar regulatory green lights elsewhere, which casts a shadow on their operational outcomes. The trajectory of VYJUVEK’s market success is subject to an array of factors, including but not limited to those within the “Risk Factors” section, with potential to derail or delay its commercial trajectory, a scenario Krystal Biotech has limited capacity to influence.
The average KRYS stock price target is $180.20, implying 14.78% upside potential.
To learn more about Krystal Biotech, Inc.’s risk factors, click here.
